	US 12,258,344 B2
	Azaaromatic amide derivatives for the treatment of cancer
Chenggang Zhu, Guangdong (CN); Xuan Yang, Guangdong (CN); Chaochun Zhang, Guangdong (CN); John J. Talley, Guangdong (CN); Chaole Chen, Guangdong (CN); Liming Bao, Guangdong (CN); and Liangliang Xu, Guangdong (CN)
Assigned to SHENZHEN FORWARD PHARMACEUTICALS CO., LTD., Guangdong (CN)
Appl. No. 17/599,806
Filed by SHENZHEN FORWARD PHARMACEUTICALS CO., LTD., Guangdong (CN)
PCT Filed Mar. 30, 2020, PCT No. PCT/CN2020/082033 § 371(c)(1), (2) Date Oct. 15, 2021, PCT Pub. No. WO2020/200158, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 201910252714.4 (CN), filed on Mar. 29, 2019; and application No. 201910616031.2 (CN), filed on Jul. 9, 2019.
Prior Publication US 2022/0177473 A1, Jun. 9, 2022
Int. Cl. C07D 471/04 (2006.01); A61K 45/06 (2006.01); C07D 251/16 (2006.01); C07D 403/04 (2006.01)

CPC C07D 471/04 (2013.01) [A61K 45/06 (2013.01); C07D 251/16 (2013.01); C07D 403/04 (2013.01)]

8 Claims

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from: